Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | PPARA | Q07869 | 7/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 7/20 | 0.32 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.31 |
| ▸ | DAGLB | Q8NCG7 | 2/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575973 | 1.00 | S1PR1 (0.41) | S1PR1S1PR3PPARAABCB11CYP1A2 | |
| SCHEMBL4575948 | 0.84 | S1PR1 (0.41) | S1PR1S1PR3PPARAABCB11CYP1A2 | |
| SCHEMBL4576077 | 0.80 | S1PR1 (0.43) | S1PR1S1PR3PPARAABCB11CYP1A2 | |
| SCHEMBL4575174 | 0.77 | PPARA (0.43) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL4575170 | 0.77 | PPARA (0.43) | PPARAABCB11CYP1A2CYP3A4TSHR | |
| SCHEMBL4575638 | 0.75 | PPARA (0.36) | S1PR1S1PR3PPARAPPARGPPARD | |
| SCHEMBL6693675 | 0.70 | S1PR1 (0.43) | S1PR1S1PR3PPARAPPARGDAGLA | |
| SCHEMBL14555317 | 0.69 | S1PR1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL4576143 | 0.68 | PPARA (0.43) | PPARAPPARGPPARD | |
| SCHEMBL4576139 | 0.68 | PPARA (0.43) | PPARAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | S1PR1 1042/4885S1PR3 1081/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.